Sanofi Pasteur, Sanofi’s vaccine division, announced that the National Ministry of Health of Costa Rica has approved Sanofi Pasteur’s tetravalent dengue vaccine, Dengvaxia®, to protect individuals 9 to 45 years of age living in endemic areas against all four serotypes of dengue. This approval in Costa Rica is the fourth registration of the dengue vaccine in Latin America, and the fifth in the world.
Sanofi Pasteur’s dengue vaccine has already been approved in following countries –
- El Salvador
Related Reading: Denguvaxia 1st regulatory approval. >> Read more